“Procalcitonin’s early assessment capability offers a crucial advantage in saving lives by identifying high-risk diabetes patients early, enhancing the monitoring of complications like retinopathy, nephropathy, and neuropathy within 24 hours for more accurate, and immediate health assessments.”

In the rapidly advancing world of healthcare, true innovation is born from visionary leadership and relentless dedication to improving patient outcomes. Today, breakthroughs in medical research are not just about discovering new treatments but revolutionizing how we approach and manage chronic diseases. Leaders in this field understand that progress requires not only cutting-edge technology but also a deep commitment to enhancing clinical decision-making and patient care.

Dr. Mehmet Ali Söylemez, Managing Director of SÖYLEMEZ INVESTMENT, exemplifies this spirit of
innovation and dedication. His groundbreaking discovery of the utility of Procalcitonin as a biomarker in Diabetes Mellitus has the potential to transform how diabetes is diagnosed and treated. Through rigorous research and over 47 publications validating his findings, Dr. Soylemez has introduced one of the most promising tools in the fight against diabetes, offering hope for more effective management and improved patient outcomes.

Driven by his passion for healthcare, Dr. Söylemez has positioned Söylemez Investment as a trailblazer in the medical field, empowering professionals to make informed clinical decisions and reducing healthcare costs, all while enhancing the quality of patient care. This revolutionary work is not only reshaping diabetes care but also setting new standards in global healthcare innovation.

We at Business Honor had the privilege of interviewing Dr. Mehmet Ali Söylemez, Managing Director of Söylemez Investment where he shared insights on how his inventions are reshaping healthcare professionals’ approach to diabetes, leading to more informed, precise, and impactful care.

Dr. Mehmet Ali Söylemez: A Visionary Leader Shaping the Future of Diabetes Care and Medical Innovation

Dr. Mehmet Ali Söylemez, MD, has embarked on a remarkable journey in the world of healthcare, driven by a clear mission to revolutionize diabetes care and empower healthcare professionals in their decision-making. His primary location is Istanbul, Turkey, where he serves as a clinical geneticist. Having completed his residency at Istanbul University,  Cerrahpasa School of Medicine  and pursued medical research at Harvard Medical School’s Countway Library of Medicine, Dr. Söylemez’s educational foundation laid the groundwork for his pioneering approach to healthcare.

Recognizing that every diabetic patient and their family has unique needs, Dr. Söylemez set out with a bold scientific goal: to create personalized diagnostic treatment plans that cater to each patient’s specific condition. His philosophy is simple yet profound—he aims to deliver tailored care that maximizes outcomes for diabetic patients while reducing healthcare costs.

Inspired by his passion for advancing diabetic treatments and technologies, Dr. Söylemez founded Söylemez Investment; a company dedicated to leveraging cutting-edge technology to transform the way diabetes is diagnosed and managed. His groundbreaking discovery of the utility of the biomarker Procalcitonin in Diabetes Mellitus has been widely celebrated in the medical community, with over 47 publications supporting the potential of this biomarker as a revolutionary tool in the fight against diabetes.

Beyond his entrepreneurial endeavors, Dr. Söylemez is a highly accomplished medical doctor and scientist, with expertise spanning clinical genetics, general surgery, and medical physiology. His research has had a profound impact on the diagnosis and management of Diabetes Mellitus and Diabetic Foot Syndrome, revolutionizing healthcare practices and improving the lives of countless patients.

Dr. Söylemez’s visionary work continues to shape the future of healthcare, blending science, technology, and compassion to create a world where diabetes care is more personalized, effective, and accessible. His dedication to innovation and patient care stands as an inspiring example of leadership in the medical field, as he pushes the boundaries of what’s possible in both technology and healthcare.

Procalcitonin: A Game-Changer in Early Detection and Management of Diabetic Complications

Diabetes mellitus impacts 529 million people worldwide and consumes 12% of global healthcare expenditure. Alarmingly, 46% of these individuals remain undiagnosed, leading to heightened risks and escalating costs. Dr. Mehmet Ali Söylemez has addressed this critical issue with a groundbreaking innovation that transforms diabetes diagnosis and management.

Dr. Söylemez, a leading clinical geneticist, discovered the potential of Procalcitonin as a biomarker for Diabetes Mellitus and Diabetic Foot Syndrome. His work, supported by over 40 peer-reviewed publications, has established Procalcitonin as a pivotal tool in diabetes care, earning recognition such as the “Best Prognostic Diabetic Biomarker Development Company 2023” award from GHP Global Healthcare and Pharmaceutical Awards.

Procalcitonin offers a significant advantage over HgbA1c by providing real-time data on diabetic complications. While HgbA1c indicates damage over a three-month period, Procalcitonin detects complications within just 24 hours, enabling faster and more effective treatment.

Dr. Söylemez holds the patent for this innovative diagnostic method, registered with the European Patent Office as EP2626704 B1. This method utilizes Procalcitonin immunoassays to diagnose pancreatic Diabetes Mellitus and Diabetic Foot Syndrome early, based on Procalcitonin levels in patients with normal blood leucocyte counts.

Unlike HgbA1c, which can be less reliable in conditions like anemia and pregnancy, Procalcitonin is an inflammatory biomarker that detects chronic low-grade inflammation in diabetes. It not only identifies late-stage complications but also detects the pre-diabetic phase, allowing for earlier intervention.

Procalcitonin’s ability to provide an early assessment of diabetic complications offers a critical advantage, potentially saving lives by identifying high-risk patients early. It enhances the monitoring of complications such as retinopathy, nephropathy, and neuropathy within a 24-hour period, leading to more accurate and immediate health assessments.

By integrating Procalcitonin into existing diabetes therapies and insulin pump systems, healthcare professionals can offer more targeted treatments, resulting in improved patient outcomes. Dr. Söylemez’s invention is poised to revolutionize the way diabetic complications are diagnosed and treated, making it a life-saving tool for millions worldwide.

Dr. Mehmet Ali Söylemez: Celebrated Innovator with Groundbreaking Patents, Prestigious Memberships, and Renowned Awards in Diabetes Diagnostics

Dr. Mehmet Ali Söylemez’s groundbreaking work in diabetes diagnostics is protected by several key patents. The U.S. Patent and Trademark Office has accepted to grant him patents for “Procalcitonin Gene Expression as a Precise Biomarker of the Aging Process” (Patent No: US 20130252254 A1) and “Diagnosis and Complication Risk Assessment of Pancreatic Diabetes Using Procalcitonin” (Patent No: US 20110263438 A1). Additionally, the European Patent Office has awarded a patent for “Diagnosis of Pancreatic Diabetes in Patients with Normal Blood Leucocyte Counts Using Procalcitonin” (Patent No: EP 2626704 B1).

Dr. Mehmet Ali Söylemez is a notable medical researcher recognized for his discovery of the use of the biomarker procalcitonin in the management of diabetes mellitus. His significant contributions to
medical science have earned him a nominations for the 2024 Harvard Medical School Warren Alpert Prize and American Medicine Nobel LASKER  AWARD.

Dr. Söylemez is also an esteemed member of several prestigious scientific associations, including the Turkish Medical Genetics Association, the American Society of Cell and Gene Therapy, the European Society of Human Genetics, and the American Society of Human Genetics.

His contributions to healthcare have been recognized with numerous awards, including the ‘European Society of Human Genetics Fellowship Award’ (2011, Amsterdam), the ‘GHP Global Healthcare and Pharmaceutical Award’ (2023, Staffordshire), and the ‘CIO Bulletin Innovation Excellence Award’ (2024, New Jersey). He has also received the ‘Silicon Review 30 Fabulous Company and Invention Awards’ (2024, New Jersey) and was named one of the ‘Most Successful Business Leaders to Watch in 2024’ (Columbus).

Dr. Mehmet Ali Söylemez, MD

”Dr. Mehmet Ali Söylemez's revolutionary discovery of Procalcitonin as a biomarker for Diabetes Mellitus has the potential to transform the landscape of diabetes care, offering a new standard of diagnostic precision that can profoundly enhance patient outcomes and reshape global healthcare practices.”